Biblio

Found 7 results
Filters: Author is Thomas, George  [Clear All Filters]
2016
R. Aggarwal, Beer, T. M., Gleave, M., Stuart, J. M., Rettig, M., Evans, C. P., Youngren, J., Alumkal, J. J., Huang, J., Thomas, G., and , “Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team”, European urology focus, vol. 2, pp. 469–471, 2016.
2015
R. Raj Aggarwal, Thomas, G., Youngren, J., Foye, A., Olson, S., Paris, P., Beer, T. M., Ryan, C. J., Witte, O., Evans, C. P., and , “Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WC”. American Society of Clinical Oncology, 2015.
E. Jay Small, Huang, J., Youngren, J., Sokolov, A., Aggarwal, R. Raj, Thomas, G., True, L. D., Zhang, L., Foye, A., Alumkal, J. J., and , “Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer ”. American Society of Clinical Oncology, 2015.
J. Woodward, King, C., Coleman, D., Lisac, R., Schwartzman, J., Wang, N., Gleave, M., Gray, J., Thomas, G., Beer, T. M., and , “Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer”. American Association for Cancer Research, 2015.
2014
E. Jay Small, Youngren, J., Thomas, G., Olson, S., Toschi, A., Foye, A., Alumkal, J. J., Rettig, M., Gleave, M. Edwin, Evans, C. P., and , “Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team ”. American Society of Clinical Oncology, 2014.
G. Thomas, Youngren, J., Ryan, C. J., Beer, T. M., Gleave, M. Edwin, Evans, C. P., Stuart, J., Rettig, M., Toschi, A., Foye, A., and , “Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2014.
E. Jay Small, Youngren, J., Beer, T. M., Ryan, C. J., Thomas, G., Pourmand, N., Reiter, R. Evan, Alumkal, J. J., Stuart, J. M., Evans, C. P., and , “The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream”. American Society of Clinical Oncology, 2014.